Ratings by Raymond James (Martin Auster)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/8/2026 | Septerna Inc | SEPN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 6/8/2026 | iBio, Inc. | IBIO | New Coverage | Outperform (N/A) |
1.82 (1.71) |
-6.04% | Details | |
| 6/1/2026 | Edgewise Therapeutics | EWTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/26/2026 | BridgeBio Pharma | BBIO | Downgrade | Market Perform (Outperform) |
70.28 (68.64) |
-2.33% | Details | |
| 5/26/2026 | Tectonic Therapeutics Inc. | TECX | Upgrade | Strong Buy (Outperform) |
28.52 (30.65) |
7.47% | Details | |
| 4/28/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | Equillium | EQ | New Coverage | Strong Buy (N/A) |
1.80 (2.93) |
62.78% | Details | |
| 4/13/2026 | Spyre | SYRE | New Coverage | Strong Buy (N/A) |
51.29 (97.69) |
90.47% | Details | |
| 3/31/2026 | Scholar Rock | SRRK | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/26/2026 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2026 | Maze Therapeutics | MAZE | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/10/2026 | Edgewise Therapeutics | EWTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/9/2026 | Eupraxia Pharmaceuticals | EPRX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/3/2026 | Scholar Rock | SRRK | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/26/2026 | Edgewise Therapeutics | EWTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/19/2026 | Eupraxia Pharmaceuticals | EPRX | New Coverage | Strong Buy (N/A) |
8.16 (6.32) |
-22.55% | Details | |
| 2/12/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2026 | Evommune Inc | EVMN | New Coverage | Strong Buy (N/A) |
16.08 (22.30) |
38.68% | Details | |
| 12/19/2025 | Septerna Inc | SEPN | New Coverage | Strong Buy (N/A) |
27.54 (35.94) |
30.5% | Details | |
| 12/12/2025 | Phathom Pharmaceuticals | PHAT | New Coverage | Strong Buy (N/A) |
14.55 (10.93) |
-24.88% | Details | |
| 12/8/2025 | Disc Medicine | IRON | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/13/2025 | Maze Therapeutics | MAZE | New Coverage | Outperform (N/A) |
32.56 (25.75) |
-20.92% | Details | |
| 10/31/2025 | Disc Medicine | IRON | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/30/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2025 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 10/17/2025 | Ascendis Pharma | ASND | New Coverage | Strong Buy (N/A) |
207.12 (232.59) |
12.3% | Details | |
| 8/7/2025 | Edgewise Therapeutics | EWTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/6/2025 | Scholar Rock | SRRK | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/1/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 7/30/2025 | Alnylam Pharmaceuticals | ALNY | New Coverage | Outperform (N/A) |
324.79 (284.16) |
-12.51% | Details | |
| 7/30/2025 | Cytokinetics | CYTK | Downgrade | Market Perform (Outperform) |
36.63 (80.12) |
118.73% | Details | |
| 7/30/2025 | Edgewise Therapeutics | EWTX | New Coverage | Strong Buy (N/A) |
14.26 (37.09) |
160.1% | Details | |
| 7/30/2025 | BridgeBio Pharma | BBIO | New Coverage | Outperform (N/A) |
46.23 (70.28) |
52.02% | Details | |
| 7/29/2025 | Scholar Rock | SRRK | New Coverage | Strong Buy (N/A) |
37.09 (49.01) |
32.14% | Details |
